KMS-11 Xenograft Model Overview
The KMS-11 xenograft model is derived from a human multiple myeloma cell line, established from the bone marrow of a patient with relapsed multiple myeloma. Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation in the bone marrow, leading to skeletal complications, anemia, and immune suppression. The KMS-11 model serves as a critical preclinical tool for studying the biology of multiple myeloma, including the tumor microenvironment, disease progression, and therapeutic resistance mechanisms. This model is particularly valuable for evaluating novel treatments aimed at targeting the bone marrow niche, plasma cell signaling, and immune system modulation in the context of myeloma.
Request a Custom Quote for KMS-11 Xenograft ModelBiological and Molecular Characteristics
The KMS-11 cell line exhibits key features of multiple myeloma, including the overexpression of surface markers such as CD38 and CD138, which are commonly expressed on malignant plasma cells. The model is also characterized by high immunoglobulin production, a hallmark of multiple myeloma. KMS-11 cells harbor mutations in the TP53 tumor suppressor gene and dysregulated signaling in pathways such as NF-kB and PI3K-Akt, which play critical roles in myeloma cell survival, proliferation, and drug resistance. Additionally, KMS-11 xenografts are known to show high expression of the angiogenic factor VEGF, contributing to tumor vasculature and enhancing tumor growth. This model is particularly useful for studying the tumor’s interactions with the bone marrow microenvironment and the mechanisms that drive metastasis and osteolysis.
| Marker | Expression Level | Function |
|---|---|---|
| CD38 | High | Marker for plasma cells and myeloma cells |
| CD138 | High | Characteristic of malignant plasma cells |
| Immunoglobulin | High | Secreted by plasma cells, hallmark of myeloma |
| VEGF | High | Angiogenesis factor that promotes tumor growth |
In Vivo Model Development and Tumorigenicity
The KMS-11 xenograft model is developed by injecting KMS-11 cells into immunocompromised mice, typically NOD/SCID or NSG mice. The cells readily form tumors in the bone marrow, accurately mimicking the natural environment of multiple myeloma in humans. Upon implantation, tumors often lead to significant bone marrow infiltration, osteolytic bone lesions, and systemic disease progression. This model is widely used to investigate drug efficacy in both localized and metastatic stages of multiple myeloma. The KMS-11 xenograft is also valuable for studying therapies targeting bone marrow interactions, such as those inhibiting osteoclast activation or promoting bone formation, as well as therapies targeting the plasma cells themselves. The model’s capacity for aggressive tumor growth and bone destruction provides a robust platform for evaluating the effectiveness of novel treatments in a clinically relevant setting.
Request a Custom Quote for KMS-11 Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of KMS-11 xenografts reveals plasma cell infiltration within the bone marrow, often accompanied by osteolytic lesions, which are characteristic of multiple myeloma. Tumors show a high degree of cellularity with pleomorphic, atypical plasma cells that are scattered throughout the bone marrow microenvironment. Immunohistochemical staining of KMS-11 xenografts typically reveals strong expression of CD38, CD138, and immunoglobulin, confirming the plasma cell origin of the tumor. Additionally, high levels of VEGF and angiogenesis are observed, indicated by CD31 staining, which highlights the presence of new blood vessels within the tumors. The model also displays markers of tumor-induced bone resorption, including increased TRAP staining, which further supports its utility in studying the bone microenvironment in myeloma.
Preclinical Applications and Drug Response
The KMS-11 xenograft model is used extensively in preclinical studies to evaluate novel therapeutics for multiple myeloma. The model is particularly valuable for assessing the effectiveness of proteasome inhibitors, such as bortezomib, and immunomodulatory drugs like lenalidomide, which are standard treatments for myeloma. Given the dysregulation of the NF-kB and PI3K-Akt pathways, the KMS-11 model is often employed to test small molecule inhibitors that target these critical survival and proliferation pathways. Additionally, the model is used to evaluate therapies aimed at reducing bone destruction in multiple myeloma, including bisphosphonates and denosumab, which target osteoclast activity. Furthermore, KMS-11 xenografts are increasingly utilized to assess the efficacy of immunotherapies, such as monoclonal antibodies targeting CD38, and adoptive T-cell therapies, which are being explored in clinical trials for multiple myeloma.
Request This Model
To request the KMS-11 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for KMS-11 Xenograft Model